Antares Pharma buy stratec
Start price
16.02.18
/
50%
€2.07
Target price
16.02.18
€5.77
Performance (%)
0.00%
End price
16.02.18
€2.07
Summary
This prediction ended on 16.02.18 with a price of €2.07. stratec's BUY prediction for Antares Pharma closed unchanged from the start price. stratec has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Antares Pharma | - | - | - | - |
| iShares Core DAX® | -0.612% | 0.567% | 12.585% | 14.838% |
| iShares Nasdaq 100 | -3.018% | -3.205% | 26.208% | 38.328% |
| iShares Nikkei 225® | -2.647% | 0.330% | 9.482% | 5.652% |
| iShares S&P 500 | -1.932% | -1.126% | 23.191% | 38.791% |
Comments by stratec for this prediction
In the thread Antares Pharma diskutieren
stratec stimmt der fundamentalen Bewertung mit dem Ergebnis 'überbewertet' nicht zu
Wednesday, the FDA approved Makena. This is a subcutaneous auto-injector to reduce the risk of preterm birth in pregnant women who have previously delivered a preterm baby. It was developed by partner Antares Pharma (ATRS). Janney Montgomery upgrade the stock from Neutral to Buy on this news. Several other analyst chimed in yesterday as well including Jefferies (Buy, $18 price target),
Cowen & Co. (Hold, $20 price target) and B Riley FBR (Hold, $16 price target)